Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) was the recipient of a significant decrease in short interest in August. As of August 31st, there was short interest totalling 326,000 shares, a decrease of 41.6% from the August 15th total of 558,500 shares. Based on an average daily volume of 1,100 shares, the short-interest ratio is currently 296.4 days.
HKMPF has been the subject of several recent analyst reports. ValuEngine downgraded shares of Hikma Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, June 8th. Morgan Stanley raised shares of Hikma Pharmaceuticals from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, July 7th. Barclays raised shares of Hikma Pharmaceuticals from an “equal weight” rating to an “overweight” rating in a research report on Friday, September 4th. Goldman Sachs Group raised shares of Hikma Pharmaceuticals from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 8th. Finally, Zacks Investment Research raised shares of Hikma Pharmaceuticals from a “hold” rating to a “buy” rating and set a $32.00 price objective for the company in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. Hikma Pharmaceuticals has an average rating of “Buy” and an average target price of $32.00.
Shares of HKMPF stock traded up $0.80 during trading hours on Wednesday, hitting $34.50. 330 shares of the company were exchanged, compared to its average volume of 2,448. The business has a 50 day moving average of $30.66 and a two-hundred day moving average of $28.28. The company has a market capitalization of $8.36 billion, a PE ratio of 23.00 and a beta of 0.49. The company has a current ratio of 1.26, a quick ratio of 0.87 and a debt-to-equity ratio of 0.05. Hikma Pharmaceuticals has a 52 week low of $19.75 and a 52 week high of $42.00.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals.
Further Reading: What is a CD ladder?
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.